Therapeutic Approach Evidence Rankings

📖 Wiki Page

company1579 wordssynced 2026-04-02

Therapeutic Approach Evidence Rankings

Overview

This page synthesizes therapeutic approaches for neurodegenerative diseases, ranking them by clinical evidence strength, mechanism validation, and development pipeline completeness. These rankings integrate data from investment activity, clinical trial outcomes, and mechanistic evidence to identify the most promising therapeutic directions.

Methodology

Ranking criteria:

Clinical Evidence (0-100): Phase 2/3 trial efficacy signals, biomarker validation, regulatory success
Mechanism Strength (0-100): Genetic validation, animal model reproducibility, human biomarker correlation
Pipeline Maturity (0-100): Active programs, programs per phase, recent advancements
Overall Score: Weighted combination (40% Clinical + 30% Mechanism + 30% Pipeline)

Alzheimer's Disease Therapeutics Rankings

Amyloid-Targeting Approaches

| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | Lecanemab (monoclonal antibody) | 95 | 90 | 85 | 90.5 | Approved |
| 2 | Donanemab (monoclonal antibody) | 90 | 85 | 80 | 85.5 | Approved |
| 3 | Aβ vaccine (ACC-001) | 60 | 80 | 70 | 70.0 | Phase 2 |
| 4 | BACE1 inhibitors (umbrecenestat) | 40 | 70 | 30 | 47.0 | Halted |
| 5 | γ-secretase modulators | 30 | 60 | 40 | 43.0 | Phase 1 |

...

Therapeutic Approach Evidence Rankings

Overview

Methodology

Ranking criteria:

Clinical Evidence (0-100): Phase 2/3 trial efficacy signals, biomarker validation, regulatory success
Mechanism Strength (0-100): Genetic validation, animal model reproducibility, human biomarker correlation
Pipeline Maturity (0-100): Active programs, programs per phase, recent advancements
Overall Score: Weighted combination (40% Clinical + 30% Mechanism + 30% Pipeline)

Alzheimer's Disease Therapeutics Rankings

Amyloid-Targeting Approaches

Evidence Synthesis: The approval of lecanemab and donanemab represents an unprecedented validation of the amyloid cascade hypothesis[@van2023]. However, the modest clinical effect size (27% slowing of decline) suggests amyloid clearance alone is insufficient for full disease modification.

Key References:

[Lecanemab CLARITY-AD Trial (2023)](https://doi.org/10.1056/NEJMoa2212948)
[Donanemab TRAILBLAZER-ALZ 2 (2023)](https://doi.org/10.1056/NEJMoa2303990)

Tau-Targeting Approaches

| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | Tau immunotherapy (gosuranemab) | 70 | 85 | 75 | 76.5 | Phase 3 |
| 2 | Tau aggregation inhibitors (MCC) | 55 | 75 | 60 | 63.5 | Phase 2 |
| 3 | Tau kinase inhibitors (GSK-3β) | 40 | 65 | 45 | 50.0 | Phase 1 |
| 4 | O-GlcNAcase inhibitors | 35 | 60 | 40 | 45.0 | Phase 1 |

Evidence Synthesis: Tau pathology shows stronger correlation with cognitive decline than amyloid[@murphy2023]. The failure of several tau immunotherapy programs (gosuranemab, semorinemab) has raised questions about tau as a therapeutic target.

Neuroprotective Approaches

| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | GLP-1 receptor agonists | 75 | 70 | 80 | 75.5 | Phase 3 |
| 2 | Neurotrophic factors (BDNF) | 45 | 80 | 40 | 55.5 | Phase 1 |
| 3 | Anti-oxidative stress | 50 | 65 | 50 | 55.0 | Phase 2 |
| 4 | Metal chelation therapy | 35 | 55 | 30 | 40.5 | Phase 2 |

Evidence Synthesis: GLP-1 agonists (liraglutide, semaglutide) show promise in AD clinical trials with effects on neuroinflammation and synaptic function[@femminella2023].

Parkinson's Disease Therapeutics Rankings

Alpha-Synuclein Targeting

| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | α-syn immunotherapy (prasinezumab) | 65 | 80 | 70 | 71.5 | Phase 2 |
| 2 | Small molecule aggregation inhibitors | 50 | 75 | 55 | 60.5 | Phase 1 |
| 3 | Gene therapy (AAV-A53T) | 40 | 70 | 35 | 48.5 | Preclinical |
| 4 | RNA targeting (ASO) | 35 | 65 | 40 | 47.0 | Phase 1 |

Evidence Synthesis: The failure of pasAD and related trials has shifted focus to earlier intervention and biomarker-driven patient selection[@pajares2020].

LRRK2-Targeting Approaches

| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | LRRK2 kinase inhibitors (DNL151) | 60 | 85 | 65 | 70.5 | Phase 2 |
| 2 | LRRK2 ASO therapy | 40 | 70 | 45 | 52.0 | Phase 1 |
| 3 | LRRK2 gene editing | 25 | 55 | 20 | 34.0 | Preclinical |

Evidence Synthesis: LRRK2 inhibitors show promise in PD, with genetic validation from G2019S mutation[@cook2023]. However, the role of LRRK2 in sporadic PD remains unclear.

Mitochondrial/Autophagy Enhancement

| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | TFEB activators | 45 | 75 | 55 | 58.5 | Phase 1 |
| 2 | Mitophagy enhancers (urolithin A) | 55 | 70 | 60 | 61.5 | Phase 3 |
| 3 | CoQ10 supplementation | 50 | 60 | 45 | 52.0 | Phase 3 |
| 4 | PINK1/Parkin activators | 30 | 65 | 25 | 40.5 | Preclinical |

Evidence Synthesis: Mitochondrial dysfunction is a central mechanism in PD, but clinical translation has been challenging[@borsche2021].

ALS Therapeutics Rankings

Gene-Targeting Approaches

| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | Tofersen (SOD1 ASO) | 85 | 95 | 80 | 87.0 | Approved |
| 2 | C9orf72 ASO | 65 | 90 | 60 | 72.0 | Phase 3 |
| 3 | FUS gene therapy | 45 | 75 | 40 | 54.0 | Phase 1 |
| 4 | ATXN2 ASO | 50 | 70 | 45 | 55.5 | Phase 1 |

Evidence Synthesis: Tofersen approval validates gene-targeting approaches in ALS[@miller2023]. The challenge remains that by the time symptoms appear, significant neuronal loss has already occurred.

Neuroprotective Approaches

| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | Riluzole (glutamate modulation) | 70 | 55 | 60 | 62.5 | Approved |
| 2 | Edaravone (anti-oxidant) | 65 | 50 | 55 | 57.5 | Approved |
| 3 | Antisense SOD1 gene therapy | 80 | 90 | 75 | 82.0 | Approved |
| 4 | Stem cell therapy | 35 | 60 | 30 | 42.0 | Phase 1 |

Cross-Disease Mechanism Rankings

Neuroinflammation Modulation

| Rank | Mechanism | AD Score | PD Score | ALS Score | Avg | Priority |
|------|-----------|----------|----------|-----------|-----|----------|
| 1 | TREM2 modulation | 80 | 70 | 60 | 70 | High |
| 2 | NLRP3 inhibition | 65 | 70 | 65 | 67 | High |
| 3 | CSF1R blockade | 60 | 55 | 70 | 62 | Medium |
| 4 | Complement inhibition | 55 | 50 | 60 | 55 | Medium |

Evidence Synthesis: Microglial modulation represents a promising cross-disease approach, particularly TREM2 variants showing strong AD genetic validation[@deczkowska2023].

Protein Homeostasis

| Rank | Mechanism | AD Score | PD Score | ALS Score | Avg | Priority |
|------|-----------|----------|----------|-----------|-----|----------|
| 1 | Autophagy induction (TFEB) | 70 | 75 | 65 | 70 | High |
| 2 | Proteasome enhancement | 55 | 60 | 70 | 62 | Medium |
| 3 | Chaperone modulation | 50 | 65 | 60 | 58 | Medium |
| 4 | Unfolded protein response | 45 | 50 | 55 | 50 | Low |

Investment Signal Synthesis

Based on pipeline activity, clinical success rates, and mechanism validation:

Highest Priority Investment Themes

Amyloid antibodies (AD): Proven efficacy, multiple approved products, expanding indication

Gene therapy/ASO (ALS/SOD1, C9orf72): High mechanism strength, precision medicine approach

GLP-1 agonists (AD/PD): Repurposing opportunity, strong safety profile

LRRK2 inhibitors (PD): Strong genetic validation, disease modification potential

Emerging Themes Requiring Further Validation

Tau immunotherapy: Strong biological rationale but clinical failures

α-synuclein targeting: Similar challenges to AD amyloid approaches

Microglial modulation: Genetic validation exists but translation early

Senolytic approaches: Early stage but high theoretical potential

Causal Chain Examples

AD Amyloid Hypothesis Causal Chain

Mermaid diagram (expand to render)

PD LRRK2 Pathway Causal Chain

Mermaid diagram (expand to render)

Knowledge Gaps and Research Priorities

AD Priority Gaps

Biomarker-driven prevention: Identifying optimal intervention window

Combination therapies: Synergistic targeting of multiple mechanisms

Resistant tau pathology: Why tau responds poorly to immunotherapy

Non-amyloid targets: APOE, TREM2, synaptic resilience mechanisms

PD Priority Gaps

α-synuclein propagation: Timing and mechanisms of spread

Genetic modifiers: Why some mutation carriers remain asymptomatic

Neuroimmune axis: Gut-brain communication in PD pathogenesis

Cellular energy crisis: Mitochondrial resilience mechanisms

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[van Dyck et al., Lecanemab in Early Alzheimer's Disease (2023) (2023)](https://doi.org/10.1056/NEJMoa2212948)

[Murphy et al., Tau as a Therapeutic Target (2023) (2023)](https://doi.org/10.1016/j.tics.2023.05.001)

[Femminella et al., GLP-1 Agonists in Alzheimer's Disease (2023) (2023)](https://doi.org/10.1016/j.jalz.2023.02.012)

[Pajares et al., Alpha-Synuclein Aggregation in Parkinson's Disease (2020) (2020)](https://doi.org/10.1016/j.tins.2020.06.004)

[Cook et al., LRRK2 Kinase Inhibitors for Parkinson's Disease (2023) (2023)](https://doi.org/10.1016/j.neuropharm.2023.109534)

[Borsche et al., Mitochondrial Dysfunction in Parkinson's Disease (2021) (2021)](https://doi.org/10.1002/mds.28706)

[Miller et al., Tofersen in SOD1-ALS (2023) (2023)](https://doi.org/10.1056/NEJMoa2204702)

[Deczkowska et al., TREM2 and Neurodegeneration (2023) (2023)](https://doi.org/10.1016/j.tins.2023.04.003)

📖 View canonical wiki page →

Therapeutic Approach Evidence Rankings

Therapeutic Approach Evidence Rankings

Overview

Methodology

Alzheimer's Disease Therapeutics Rankings

Amyloid-Targeting Approaches

Therapeutic Approach Evidence Rankings

Overview

Methodology

Alzheimer's Disease Therapeutics Rankings

Amyloid-Targeting Approaches

Tau-Targeting Approaches

Neuroprotective Approaches

Parkinson's Disease Therapeutics Rankings

Alpha-Synuclein Targeting

LRRK2-Targeting Approaches

Mitochondrial/Autophagy Enhancement

ALS Therapeutics Rankings

Gene-Targeting Approaches

Neuroprotective Approaches

Cross-Disease Mechanism Rankings

Neuroinflammation Modulation

Protein Homeostasis

Investment Signal Synthesis

Highest Priority Investment Themes

Emerging Themes Requiring Further Validation

Causal Chain Examples

AD Amyloid Hypothesis Causal Chain

PD LRRK2 Pathway Causal Chain

Knowledge Gaps and Research Priorities

AD Priority Gaps

PD Priority Gaps

External Links

See Also

References